Researchers have identified how cerebrovascular disease (CeVD) disrupts brain connectivity, contributing to cognitive decline and neurodegeneration alongside Alzheimer’s disease (AD).
(OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...